Basic Information
| LncRNA/CircRNA Name | LINC01714 |
| Synonyms | NA |
| Region | GRCh38_1:8202429-8215210 |
| Ensemble | ENSG00000227634 |
| Refseq | NR_125998 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Gemcitabine | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cholangiocarcinoma |
| ICD-0-3 | NA |
| Methods | RNA-seq, qRT-PCR, Western blot Assays, RNAi, RIP |
| Sample | CCA cell lines HuCCT1 and CCLP1 |
| Expression Pattern | down-regulated |
| Function Description | LINC01714 was found to be recurrently downregulated in CCA tumor samples. Our results revealed that decreased LINC01714 expression was associated with the poor survival of CCA patients. Our observations revealed that LINC01714 suppressed the proliferation, migration, and invasion abilities of CCA cells both in vitro and in vivo. Furthermore, we found that LINC01714 physically interacted with Forkhead Box O3 (FOXO3) and increased the FOXO3 protein level. In addition, LINC01714 could decrease the phosphorylation level of FOXO3. |
| Pubmed ID | 31902744 |
| Year | 2020 |
| Title | LINC01714 Enhances Gemcitabine Sensitivity by Modulating FOXO3 Phosphorylation in Cholangiocarcinoma |
External Links
| Links for LINC01714 | GenBank HGNC NONCODE |
| Links for cholangiocarcinoma | OMIM COSMIC |